On April 25, 2025 NETRIS Pharma, a clinical-stage private biopharmaceutical company developing a new class of therapeutics targeting Netrin-1, reported positive interim results from the ongoing ImmunoNET Phase II trial of its lead candidate NP137 (Press release, Netris Pharma, APR 25, 2025, View Source [SID1234652145]). The multicenter, open-label, proof of concept study is designed to evaluate the clinical and biological activity of NP137 as an add-on therapy in patients with advanced or metastatic Head & Neck Cancer and Non-Small Cell Lung Cancer (NSCLC) who have progressed under standard immunotherapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The interim analysis met both the primary and key secondary endpoints in secondary refractory patients. Such analysis confirms NP137 excellent safety profile and its potential to overcome secondary resistance to leading immunotherapies. Clinical benefits were observed in half of the patients with Head & Neck and NSCLC cancers who had previously progressed under approved immunotherapy.
« These interim results mark a major milestone in our mission to develop drugs that overcome therapy resistance » said Patrick Mehlen, CEO of NETRIS Pharma. « We are excited by the potential of NP137 to restore patients sensitivity to immunotherapy-based treatments and to deliver a new treatment solution for patients with limited options ».
Upcoming Data Presentations
Comprehensive study design and interim results will be presented at two of the world’s leading oncology congresses: the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress in 2025, underscoring the global significance of these findings.
« We look foward to sharing these important data with the oncology community at ASCO (Free ASCO Whitepaper) and ESMO (Free ESMO Whitepaper), and to advancing NP137 into the next phase of development » added Dr. Jérome Fayette, Medical Oncologist at Centre Léon Bérard and Principal Investigator of the ImmunoNet study.
About NP137
NP137 is a humanized monoclonal antibody (IgG1) targeting netrin-1, a protein overexpressed in a large proportion of human cancers and associated with disease severity and resistance to therapy. By blocking netrin-1, NP137 is designed to restore apoptosis and reverse epithelial-to-mesenchymal transition (EMT), addressing critical mechanisms of resistance that limit the effectiveness of immune checkpoint inhibitors. Preclinical and early clinical studies have shown that NP137 has anti-cancer effects both as a monotherapy and in combination with chemotherapy or immunotherapy, with a favorable safety profile.